T1	intervention 43 77	transdermal 4-hydroxytamoxifen gel
T2	control 90 99	tamoxifen
T3	eligibility 103 152	women with ductal carcinoma in situ of the breast
T4	No-of-participants 482 494	Twenty-seven
T5	duration 587 600	6 to 10 weeks
T6	outcome-Measure 820 849	Ki67 labeling in DCIS lesions
T7	outcome-Measure 888 894	plasma
T8	outcome-Measure 933 968	sex hormone-binding globulin (SHBG)
T9	outcome-Measure 896 932	insulin-like growth factor-1 (IGFI),
T10	outcome-Measure 974 1008	coagulation protein concentrations
T11	outcome 1026 1052	Posttherapy Ki67 decreased
T12	intervention-value 1056 1060	3.4%
T13	control-value 1078 1082	5.1%
T14	outcome 1148 1165	Mean plasma 4-OHT
T15	outcome 1249 1299	mean breast adipose tissue concentrations of 4-OHT
T16	outcome 1412 1463	plasma SHBG, factor VIII, and von Willebrand factor
T17	outcome 1494 1517	plasma IGFI with oral-T
T18	adverse-effect 1556 1567	hot flashes
